Krop Julie
SEC insider (Form 3/4/5 filer). CIK 0001643127. Director at Aquestive Therapeutics, Inc. (AQST) and 1 other issuer. 6 reported Form 4/5 transactions since Sep 2024; latest on Jun 23, 2026. Located in MINNEAPOLIS, MN.
Companies Krop Julie has filed insider reports for
- Aquestive Therapeutics, Inc. (AQST): Director
- DiaMedica Therapeutics Inc. (DMAC): Officer, Chief Medical Officer
Krop Julie
CIK: 0001643127
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Jun 23, 2026AQST
Aquestive Therapeutics, Inc.
ExerciseDirect25K shares at avg. $0.71$18K - Jun 23, 2026AQST
Aquestive Therapeutics, Inc.
SaleDirect25K shares at avg. $5.02$125K - Jun 10, 2026AQST
Aquestive Therapeutics, Inc.
AwardDirectStock Option (Right to Purchase)
50.5K shares- - Jun 1, 2026DMAC
DiaMedica Therapeutics Inc.
AwardDirectStock Option (right to buy)
67.5K shares- - Aug 11, 2025DMAC
DiaMedica Therapeutics Inc.
AwardDirectStock Option (right to buy)
450K shares- - Jun 11, 2025AQST
Aquestive Therapeutics, Inc.
AwardDirectStock Option (Right to Purchase)
42K shares at avg. $3.41-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 23, 2026 |  AQST Aquestive Therapeutics, Inc. | Exercise | 25,000 | $0.71 | $17,830 | Direct |
| Jun 23, 2026 | AQST Aquestive Therapeutics, Inc. | Sale | 25,000 | $5.02 | $125,393 | Direct |
| Jun 10, 2026 | AQST Aquestive Therapeutics, Inc. | Award Stock Option (Right to Purchase) | 50,500 | - | - | Direct |
| Jun 1, 2026 |  DMAC DiaMedica Therapeutics Inc. | Award Stock Option (right to buy) | 67,500 | - | - | Direct |
| Aug 11, 2025 | DMAC DiaMedica Therapeutics Inc. | Award Stock Option (right to buy) | 450,000 | - | - | Direct |
| Jun 11, 2025 | AQST Aquestive Therapeutics, Inc. | Award Stock Option (Right to Purchase) | 42,000 | $3.41 | - | Direct |
1-6 of 6 transactions